+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

EU Grant Development Voucher

European Alliance of Associations for Rheumatology (EULAR)

The EU Grant Development Voucher provides rapid funding for purchasing professional writing support for EU grants, such as the European Research Council (ERC) or Horizon Europe. Supported grant projects must address the needs of people with rheumatic and musculoskeletal diseases (RMDs).

Budget and financial requirements

- The budget may not exceed EUR 5,000 per project.

- If awarded a voucher, all funds will need to be spent within 12 months of account establishment.

- Cost sharing and attempts to raise funds from other sources are encouraged.

Application requirements

-Awardees will be required to present proof-of-payment as outlined in the budget and complete the follow-up impact survey.

AI Based Application Success Predictor

1. Strong relevance to rheumatic and musculoskeletal diseases (RMDs)

The most competitive applications directly address:

rheumatoid arthritis,
psoriatic arthritis,
lupus,
ankylosing spondylitis,
osteoarthritis,
vasculitis,
pediatric rheumatology,
autoimmune inflammation,
connective-tissue diseases,
musculoskeletal rehabilitation.

Clear alignment with EULAR’s RMD mission is essential.

2. Strong translational and patient-care impact

EULAR reviewers strongly favor projects likely to:

improve diagnosis,
optimize treatment strategies,
improve long-term outcomes,
reduce disability,
enhance rehabilitation,
improve quality of life,
influence rheumatology practice guidelines.

Clinical applicability is one of the strongest predictors of competitiveness.

3. Strong methodological rigor

Competitive applications generally demonstrate:

robust clinical or laboratory design,
validated outcome measures,
reproducibility,
realistic recruitment strategies,
strong statistical planning,
feasible timelines.

Weak methodology is a major reviewer concern across EULAR funding schemes.

4. Multinational and multidisciplinary collaboration

High-scoring applications often involve:

rheumatologists,
immunologists,
rehabilitation specialists,
epidemiologists,
imaging experts,
data scientists,
allied health professionals,
patient organizations.

EULAR strongly values pan-European collaboration and knowledge exchange.

5. Strong preliminary or pilot data

Successful proposals frequently include:

pilot cohort data,
biomarker findings,
feasibility studies,
imaging/genomic datasets,
proof-of-concept therapeutic evidence,
prior publications.

Even smaller EULAR “voucher” programs prioritize projects with credible feasibility evidence.

6. Patient-centered and implementation-focused research

EULAR increasingly prioritizes:

patient-reported outcomes,
rehabilitation science,
healthcare delivery,
shared decision-making,
quality-of-life measures,
long-term disease management,
access-to-care improvements.

Projects with direct practice implications often perform strongly.

7. Strong international training and networking potential

For fellowships and exchange grants, reviewers heavily assess:

international collaboration plans,
mobility and training value,
knowledge-transfer potential,
long-term partnership development,
future rheumatology leadership.

EULAR strongly supports educational visits, scientific exchange, and international cooperation.

8. Innovation balanced with feasibility

Competitive applications usually combine:

innovative immunology,
precision rheumatology,
advanced imaging,
AI/data science,
digital health tools,
translational therapeutics

with realistic execution plans.

Overly ambitious proposals without clear feasibility often score poorly.

9. Strong publication and academic track record

Important predictors include:

rheumatology publications,
conference abstracts,
EULAR Congress presentations,
collaborative productivity,
prior grants,
evidence of independent scientific contribution.

Research productivity strongly influences reviewer confidence.

10. Potential for future larger European funding

Reviewers favor projects likely to:

generate Horizon Europe/NIHR/ERC funding,
support multicenter consortia,
produce publishable outcomes,
influence European rheumatology guidelines,
build sustainable research networks.

EULAR funding is frequently viewed as seed or developmental support.

Common Reasons for Rejection

Frequent reviewer concerns include:

insufficient innovation,
weak translational significance,
poor feasibility,
limited European collaboration,
inadequate statistical planning,
weak patient relevance,
insufficient preliminary evidence,
unrealistic scope.

Specialties

Rheumatology

Eligibility Requirements

- Researchers and Health Professionals from all EULAR-affiliated countries.

- Although the primary metric for evaluation will be the quality of the proposal, in the event of over

-subscription and otherwise equitable adjudication of merit, weighting will be given to those applications coming from regions in which rheumatology research has received lower levels of research support on a historical basis, or that has been under-represented in abstract submission rates to the EULAR Congress.

- Investigators are eligible to receive one voucher award per year. Only one application per research group per cycle will be permitted

Sponsor Details

Sponsor Institute/Organizations: European Alliance of Associations for Rheumatology (EULAR)

Sponsor Type: Corporate/Non-Profit

Address: Seestrasse 240 CH 8802 Kilchberg (Zurich)

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity